卡培他滨联合替吉奥对结直肠癌患者血清EGFR及HER-2表达的影响

Effect of capecitabine combined with tegiol on the expression of serum EGFR and HER-2 in patients with colorectal cancer

目的探究卡培他滨联合替吉奥对结肠癌患者血清表皮生长因子受体(EGFR)及人类表皮生长因子受体-2(HER-2)表达的影响。方法选取我院2017年7月至2018年12月收治的208例晚期结直肠癌患者,随机分为对照组和研究组,各104例,前者给予单纯卡培他滨口服治疗,后者进行卡培他滨联合替吉奥治疗,比较两组患者的临床疗效、不良反应发生情况及两组患者治疗前后血清EGFR及HER-2水平的变化情况。结果研究组患者有效率、CR构成比均显著高于对照组(79.81%vs.50.96%,32.69%vs.12.50%,P<0.01);研究组患者胃肠道反应(30.77%vs.13.46%)和粒细胞降低(37.50%vs.11.54%)的发生率显著高于对照组(P<0.01);治疗后,研究组患者血清EGFR[(4.27±1.34)mg/L vs.(6.49±1.62)mg/L]和HER-2[(4.93±1.68)mg/L vs.(8.40±1.94)mg/L]水平显著低于对照组,差异均有统计学意义(P<0.05)。结论卡培他滨联合替吉奥治疗晚期结直肠癌能够取得良好的短期疗效,有助于提高患者的生存率,联合用药耐受良好,同时能够降低患者血清EGFR和HER-2水平,改善预后。

Objective To investigate the effects of capecitabine combined with tegiol on the expression of serum epidermal growth factor receptor(EGFR)and human epidermal growth factor receptor-2(HER-2)in patients with colon cancer.Methods Totally 208 patients with advanced colorectal cancer admitted to our hospital from July 2017 to December 2018 were randomly divided into control group and study group,104 cases in each group.The former was treated with capecitabine alone,while the latter was treated with capecitabine combined with tegio.The clinical efficacy and adverse reactions of the two groups were compared.The serum levels of EGFR and HER-2 were compared before and after treatment.Results The effective rate and CR rate of study group were higher than those of control group(79.81%vs.50.96%,32.69%vs.12.50%,P<0.01).The incidence of gastrointestinal reaction(30.77%vs.13.46%)and granulocyte decrease(37.50%vs.11.54%)in study group was higher than that in control group(P<0.01).After treatment,the serum levels of EGFR[(4.27±1.34)mg/L vs.(6.49±1.62)mg/L]and HER-2[(4.93±1.68)mg/L vs.(8.40±1.94)mg/L]in study group were lower than those in control group(P<0.01).Conclusion Capecitabine combined with tegio in the treatment of advanced colorectal cancer can achieve good short-term efficacy and help to improve the survival rate of patients with good drug tolerance.It can also reduce the serum levels of EGFR and HER-2 and improve the prognosis of patients.